Dulaglutide Dosing for Type 2 Diabetes
Start dulaglutide at 0.75 mg subcutaneously once weekly, then increase to 1.5 mg once weekly after at least 4 weeks if additional glycemic control is needed. For patients requiring further glucose lowering, escalate in 1.5 mg increments (to 3 mg, then 4.5 mg) after at least 4 weeks at each dose, with a maximum of 4.5 mg weekly 1.
Initial Dosing
- Starting dose: 0.75 mg once weekly subcutaneously 2, 3
- Administer at any time of day, with or without food 1
- Injection sites: abdomen, thigh, or upper arm 1
Titration Schedule
The key to successful dulaglutide therapy is gradual dose escalation to minimize gastrointestinal side effects 2. The FDA-approved titration pathway is:
- Week 0-4: 0.75 mg once weekly
- Week 4+: Increase to 1.5 mg once weekly if additional glycemic control needed
- After ≥4 weeks at 1.5 mg: May increase to 3 mg once weekly
- After ≥4 weeks at 3 mg: May increase to 4.5 mg once weekly (maximum dose) 1
Most patients in real-world practice start at 1.5 mg (49-62% of incident users) and remain on this dose long-term (66-88% at 12 months) 4, 5. However, starting at the lower 0.75 mg dose reduces gastrointestinal adverse events and improves adherence, particularly in GLP-1 RA-naïve patients 2.
Dosing for Cardiovascular Benefit
For cardiovascular risk reduction, initiate at 0.75 mg weekly and titrate to 1.5 mg or the maximally tolerated dose 2. The REWIND cardiovascular outcomes trial demonstrated MACE reduction with dulaglutide, supporting its use in patients with established cardiovascular disease or multiple cardiovascular risk factors 6.
Renal Dosing Considerations
No dose adjustment is required for renal impairment 3. However:
- eGFR <45 mL/min/1.73 m²: Use is not recommended per some guidelines 2
- eGFR ≥30 mL/min/1.73 m²: No dosage adjustment required per other sources 3
- Monitor renal function in patients with renal impairment who develop severe gastrointestinal reactions 1
This discrepancy in guidelines reflects evolving evidence, with more recent 2022 guidelines 3 being more permissive than 2020 guidance 2.
Missed Dose Management
If a dose is missed, administer as soon as possible only if there are at least 3 days (72 hours) until the next scheduled dose 1. If less than 3 days remain, skip the missed dose and resume the regular weekly schedule.
Clinical Outcomes by Dose
Real-world evidence demonstrates:
- HbA1c reduction: -1.01% to -1.51% depending on baseline characteristics 7
- Weight loss: -2.8 kg to -4.1 kg, with higher doses producing greater weight reduction 8
- Durability: Glycemic and weight benefits sustained beyond 3 years of continuous use 9
Earlier initiation (fewer prior oral antidiabetic drugs) correlates with better outcomes: patients on 1 oral agent achieved 68% HbA1c <7% target versus 33% in those on ≥3 agents 7.
Common Pitfalls to Avoid
Rapid dose escalation: Increases nausea, vomiting, and treatment discontinuation. Always wait at least 4 weeks between dose increases 2, 1
Starting at 1.5 mg in GLP-1 RA-naïve patients: While common in practice, starting at 0.75 mg improves tolerability 2
Discontinuing for transient GI symptoms: Nausea typically diminishes over time. Consider slowing titration rather than stopping 2
Ignoring contraindications: Absolute contraindications include personal/family history of medullary thyroid carcinoma or MEN2 syndrome 1
Using in severe gastroparesis: Not recommended in patients with severe gastrointestinal disease 1
Dose Escalation to Higher Doses (3 mg and 4.5 mg)
The 3 mg and 4.5 mg doses provide incremental HbA1c reduction (-1.31% and -1.40% respectively) and greater weight loss (-3.9 kg and -4.1 kg) compared to 1.5 mg 8. These higher doses are appropriate for patients requiring additional glycemic control after at least 4 weeks at 1.5 mg, with an acceptable safety profile 8.